Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience

Bone Marrow Transplant. 2021 Jun;56(6):1455-1457. doi: 10.1038/s41409-020-01174-w. Epub 2021 Jan 29.

Affiliations

¹ Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy. antonellabruzzese@msn.com.
² Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. antonellabruzzese@msn.com.
³ Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy.

PMID: 33514926
DOI: 10.1038/s41409-020-01174-w

No abstract available

Publication types

Letter

MeSH terms

Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / therapy
Mutation
Sorafenib / therapeutic use
fms-Like Tyrosine Kinase 3 / genetics

Substances

Sorafenib
FLT3 protein, human
fms-Like Tyrosine Kinase 3